All News

question-mark-1872634_640.jpg

ICYMI: What to do about pre-clinical RA?

d Robert Chao, MD

RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, especially what to do regarding pre-clinical RA.

Dr. Kevin Deane started the discussion by mapping out a very complex course of RA, beginning with a person’s genetic and environmental risk factors. What are Dr. Deane’s recommendations for management of pre-RA patients?

Read Article
pneumocystis,PJP

PJP Prophylaxis Needed with Steroids and Rituximab

d Jack Cush, MD

Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening infection in immunocompromised patients. The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving rituximab (RTX).

Read Article

RheumThoughts: An Opportunity to Say Yes Hi, I am Dr. Kathryn Dao ( @KDAO2011 ) a rheumatologist and senior editor for the RheumNow Women in Rheumatology Campaign. I wanted to share you with an opportunity. An Opportunity to Say Yes. https://t.co/dJKWFAASV9 https://t.co/Cm4vn563Pz

Links:

Dr. John Cush RheumNow ( View Tweet)
Romania to U.S.: My Journey to a Permanent Residency One in four practicing physicians in the United States are international medical graduates. I am one of them. Dr. Maria Danila shares her IMG experience. https://t.co/vpxyosojxc https://t.co/FrIuLyvgXS

Links:

Dr. John Cush RheumNow ( View Tweet)
Another review on the annual salaries of different specialists.... https://t.co/bkkcIR5pa5

Links:

Dr. John Cush RheumNow ( View Tweet)

Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development: - Obinutuzumab - Dapirolizumab - Deucravacitinib - Litifilimab - Atacicept - Telitacicept https://t.co/jMLlRZuK6e https://t.co/8K0dYLieAH

Links:

Dr. John Cush RheumNow ( View Tweet)
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: No is a complete sentence Dr. Rachel Tate ( @uptoTate ) shares her POV. https://t.co/0xzTobgmIQ https://t.co/YvEUMsqLyV

Links:

Dr. John Cush RheumNow ( View Tweet)
25 Great Women in Rheumatology This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? I'm sharing the responses. https://t.co/N1zqs3TJuv https://t.co/LXDxnXUaG9

Links:

Dr. John Cush RheumNow ( View Tweet)
Denosumab Reduces Type II Diabetes Risk The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/7SMjp258gX https://t.co/SAUmahwV9J

Links:

Dr. John Cush RheumNow ( View Tweet)
How Being a Patient Taught Me to Be a Better Doctor Dr. Marcella Ferrada ( @maferradastrong ) shares her experience having a rare disease and how it positively impacted her skills as a physician. https://t.co/eUHzPTjRv8 https://t.co/rTIfyLwVLY

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: No is a complete sentence Dr. Rachel Tate ( @uptoTate ) shares her POV. https://t.co/TGcFuGl4Lp https://t.co/N0bItVkHjM

Links:

Dr. John Cush RheumNow ( View Tweet)
25 Great Women in Rheumatology This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? I'm sharing the responses. https://t.co/0d7SkgpcN5 https://t.co/nQVfs5oMFL

Links:

Dr. John Cush RheumNow ( View Tweet)
Narrative Medicine Dr. Aviya Lanis shares with us how narrative medicine helped her become a more engaging doctor. https://t.co/YJdsa50FBF https://t.co/7D3DiBnqaK

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies 4661 pts. Corticosteroids reduced mortality in more severe CAP (RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/dj7zABqQ3r https://t.co/Mb4g7ICdX9

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of IV NA Thiosulphate for Calciphylaxis in CKD shows NO improvement in skin lesion (RR 1.23; 0.85-1.78) or survival (HR 0.82; 0.57-1.18); based on 19 studies and 422 pts https://t.co/0uyHhWJpFJ https://t.co/dkRgRjh2cH

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/PYsTGnejOF https://t.co/AqOiiZm3uI

Links:

Dr. John Cush RheumNow ( View Tweet)
NIH generated FDA approved drug costs ~$1.4-1.7 billlion for each 1st-in-class drug (vs estimated pharma industry cost of $1.5 billion per approved Rx). Govt may serve as early investor in pharma innovations. ~1/2 total R&D investment comes from US govt https://t.co/PORuiowRBy? https://t.co/urPkqX98A6

Links:

Dr. John Cush RheumNow ( View Tweet)
×